HomeContactहिन्दीதமிழ்
Covaxin 3rd phase clinical trials show 77.8% efficacy rate
Science & Technology
Covaxin 3rd phase clinical trials show 77.8% efficacy rate
July 03, 2021
1 min
हिन्दी
  • India’s indigenous vaccine COVAXIN has shown an efficacy of 77.8% in symptomatic Covid-19 cases in phase 3 clinical trials.
  • COVAXIN has shown an efficacy rate of 93% against severe Covid-19 disease and 65% efficacy against the Delta variant.
  • COVAXIN has been developed by Bharat Biotech in partnership with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV).
  • COVAXIN has received emergency use authorizations in 16 countries.
  • Bharat Biotech is in discussions with the World Health Organization (WHO) to add COVAXIN to their list of approved vaccines.

Tags

Indian Council of Medical ResearchWorld Health OrganizationVaccineBiotechnologyCovaxinBharat BiotechNational Institute of Virology
Previous Article
Atul Keshap appointed as US envoy to India

Related Posts

WHO issues recommendations for Gene-editing
July 13, 2021
1 min
© 2021, All Rights Reserved.
Made with in भारत

Language

हिन्दीதமிழ்

Legal Stuff

Social Media